The Frontline Treatment of Peripheral T-Cell Lymphoma: Current and Future Strategies
Please choose a module from the options below. To receive credit and a certificate, you must complete all of the modules in this activity.
Welcome to this Med-IQ Select on peripheral T-cell lymphoma (PTCL). Med-IQ Select is a unique online educational offering that allows you to pick and choose the content you'd like to view--in any order and at your convenience.
To get started, click "view" on any of the modules below. To receive credit and a certificate, you must complete all of the modules.
Time to Complete: 11 minutes
Time to Complete: 7 minutes
Time to Complete: 12 minutes
Complete all of the above modules to earn credit;
0 out of 3 modules complete
Steven Horwitz, MD
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Christie Avraamides, PhD
Clinical Content Manager
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Edward Allan Racela Sison, MD
Missouri City, TX
Upon completion, participants should be able to:
- Incorporate clinical evidence on the benefits and limitations of available therapeutic regimens into individualized treatment decisions for patients with newly diagnosed PTCL, including those whose tumors express CD30
- Discuss the clinical evidence regarding emerging therapeutic strategies in treatment-naïve PTCL
This activity is intended for hematologist-oncologists and other healthcare professionals involved in making treatment decisions for patients with PTCL.
Statement of Need
PTCL accounts for 15% of non-Hodgkin lymphoma cases. Traditionally, its treatment has reflected that of B-cell lymphoma; however, this treatment paradigm is associated with high relapse rates. Fortunately, a novel targeted therapy is now available for patients with treatment-naïve PTCL whose tumors express CD30. Therefore, hematology/oncology professionals need to have a good working knowledge of the clinical evidence on the safety and efficacy of this novel therapy and understand the clinical significance of CD30 expression to best care for their patients with CD30-positive PTCL. In addition, there is an active research pipeline investigating the utility of novel therapeutic strategies in newly diagnosed PTCL, and clinicians need to have a solid understanding of the efficacy and toxicity outcomes associated with these novel treatments to enable the individualized and appropriate use of these agents in clinical practice as they become available.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: August 2, 2019
Expiration Date: August 1, 2020
Estimated Time to Complete This Activity: 30 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Steven Horwitz, MD
Consulting fees/advisory boards: ADC Therapeutics, Affimed, Aileron Therapeutics, Angimmune, BeiGene, Corvus Pharmaceuticals, Forty Seven, Infinity Pharmaceuticals/Verastem, Innate Pharma, Kura Oncology, Kyowa Hakka Kirin, Merck & Co., Inc., Millennium: The Takeda Oncology Company, miRagen Therapeutics, Mundipharma, Portola Pharmaceuticals, Seattle Genetics, Syros Pharmaceuticals
Contracted research: ADC Therapeutics, Aileron Therapeutics, Celgene Corporation, Forty Seven, Infinity Pharmaceuticals/Verastem, Kyowa Hakka Kirin, Millennium: The Takeda Oncology Company, Seattle Genetics, Trillium Therapeutics
Edward Allan Racela Sison, MD
Salary: Covance, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Laboratory Corporation of America, United Health Group Inc.
The peer reviewers and other activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Seattle Genetics.
© 2019 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.